Cognitive impairment and hippocampal alpha-synuclein change in a rat model of chronic cerebral hypoperfusion

doi:10.3969/j.issn.2095-4344.0311

Abstract

Abstract:

BACKGROUND: Preliminary studies have shown that chronic cerebral hypoperfusion (CCH)-induced impairment of cognitive function in rats is associated with increased silent synapses in the hippocampus. Meanwhile, alpha-synuclein can lead to cognitive impairment and mitochondrial dysfunction.
OBJECTIVE: To observe the changes of cognitive function and hippocampal alpha-synuclein in rats with CCH.
METHODS: The rat model of CCH was prepared by permanent bilateral common carotid artery occlusion, and the rats without common carotid artery occlusion were used as controls. The cognitive function was detected by an open field and a Morris water maze at 1 and 3 months after modeling. Afterwards, the expression level of mitochondrial alpha-synuclein in the hippocampal region was detected by western blot assay. Changes of alpha-synuclein in the hippocampus were detected by immunofluorescence.
RESULTS AND CONCLUSION: CCH group had more significantly decreased escape latency in Morris water maze test, and increasing distance traveled in the open filed test, compared with the control group (P< 0.05). Western blot assay results showed that the expression level of alpha-synuclein in the hippocampal mitochondrion of rats with CCH was significantly higher than that in the control group (P < 0.05). Immunofluorescence results revealed that the level of alpha-synuclein was significantly increased in the CCH group compared with the control group (P < 0.05). Our results suggest that there is an increase in alpha-synuclein in the hippocampus of rats with CCH, which may be involved in the cognitive impairment following CCH.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Brain Ischemia, Hippocampus, alpha-synuclein, Mitochondria, Tissue Engineering

CLC Number:

R318

He Jing1, Huang Yan1, Du Guo2, Wang Zhi-qiang2, Xiang Yang2, Wang Qing-song1, 2. Cognitive impairment and hippocampal alpha-synuclein change in a rat model of chronic cerebral hypoperfusion[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(20): 3230-3236.

Figures/Tables 2

References

[1] Wirth M, Pichet Binette A, Brunecker P,et al. Divergent regional patterns of cerebral hypoperfusion and gray matter atrophy in mild cognitive impairment patients. J Cereb Blood Flow Metab 2017;37(3): 814-824.

[2] Gorelick PB, Counts SE, Nyenhuis D. Vascular cognitive impairment and dementia. Biochim Biophys Acta. 2016;1862 (5):860-868.

[3] Zhu J, Wang Y, Li J, Deng J,et al. Intracranial artery stenosis and progression from mild cognitive impairment to Alzheimer disease. Neurology 2014; 82(10): 842-849.

[4] Han H, Qian Q, Yu Y,et al. Lamotrigine attenuates cerebral ischemia-induced cognitive impairment and decreases beta-amyloid and phosphorylated tau in the hippocampus in rats. Neuroreport 2015; 26(12): 723-727.

[5] Liu F, Jiang YJ, Zhao HJ,et al. Electroacupuncture ameliorates cognitive impairment and regulates the expression of apoptosis-related genes Bcl-2 and Bax in rats with cerebral ischaemia-reperfusion injury. Acupunct Med 2015;33(6): 478-484.

[6] Wang Z, Fan J, Wang J,et al. Chronic cerebral hypoperfusion induces long-lasting cognitive deficits accompanied by long-term hippocampal silent synapses increase in rats. Behav Brain Res 2016; 301: 243-252.

[7] Thomas T, Miners S, Love S.Post-mortem assessment of hypoperfusion of cerebral cortex in Alzheimer's disease and vascular dementia. Brain 2015;138(Pt 4): 1059-1069.

[8] Iadecola C. The pathobiology of vascular dementia. Neuron . 2013; 80(4): 844-866.

[9] O'Brien JT, Thomas A. Vascular dementia. Lancet 2015; 386(10004): 1698-706.

[10] 王璐,霍帅,王亚飞,等. 慢性脑缺血模型大鼠神经突触可塑性与N-甲基-D-天门冬氨酸型受体[J]. 中国组织工程研究,2015, 19(40):6498-6503.

[11] Du J, Ma M, Zhao Q,et al. Mitochondrial bioenergetic deficits in the hippocampi of rats with chronic ischemia-induced vascular dementia. Neuroscience.2013;231:345-352.

[12] Li N, Kong X,Ye R,et al.Age-related differences in experimental stroke: possible involvement of mitochondrial dysfunction and oxidative damage. Rejuvenation Res.2011; 14(3): 261-273.

[13] Li H, Liu Y, Lin LT, et al. Acupuncture reversed hippocampal mitochondrial dysfunction in vascular dementia rats. Neurochem Int 2016; 92: 35-42.

[14] 代海滨,苗晓蕾,嵇晴,等. 线粒体及凋亡相关信号途径在脑缺血性损伤细胞死亡过程中的重要角色[J].中国组织工程研究,2015, 19(15): 2425-2430.

[15] Yue ZY, Dong H, Wang YF, et al. Propofol prevents neuronal mtDNA deletion and cerebral damage due to ischemia/reperfusion injury in rats. Brain Res.2015;1594:108-114.

[16] Reeve AK, Ludtmann MH, Angelova PR, et al. Aggregated alpha-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons. Cell Death Dis.2015;6: e1820.

[17] Tapias V, Hu X, Luk KC, et al. Greenamyre, Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci .2017; 74(15):2851-2874.

[18] Hu X, Rea HC, Wiktorowicz JE, et al. Proteomic analysis of hypoxia/ischemia-induced alteration of cortical development and dopamine neurotransmission in neonatal rat. J Proteome Res.2006;5(9):2396-2404.

[19] Yoon DK, Hwang IK, Yoo KY, et al. Comparison of alpha-synuclein immunoreactivity and protein levels in ischemic hippocampal CA1 region between adult and aged gerbils and correlation with Cu,Zn-superoxide dismutase. Neurosci Res.2006;55(4): 434-441.

[20] Unal-Cevik I, Gursoy-Ozdemir Y, Yemisci M, et al. Alpha-synuclein aggregation induced by brief ischemia negatively impacts neuronal survival in vivo: a study in [A30P]alpha-synuclein transgenic mouse. J Cereb Blood Flow Metab.2011;31(3): 913-923.

[21] Kim T, Mehta SL, Kaimal B, et al. Vemuganti, Poststroke Induction of alpha-Synuclein Mediates Ischemic Brain Damage. J Neurosci. 2016;36(26):7055-7065.

[22] Choi JY, Cui Y, Kim BG. Interaction between hypertension and cerebral hypoperfusion in the development of cognitive dysfunction and white matter pathology in rats. Neuroscience. 2015;303: 115-125.

[23] Jing Z, Shi C, Zhu L, et al. Chronic cerebral hypoperfusion induces vascular plasticity and hemodynamics but also neuronal degeneration and cognitive impairment. J Cereb Blood Flow Metab.2015;35(8):1249-1259.

[24] Wan Q, Ma X, Zhang ZJ, et al. Ginsenoside Reduces Cognitive Impairment During Chronic Cerebral Hypoperfusion Through Brain-Derived Neurotrophic Factor Regulated by Epigenetic Modulation. Mol Neurobiol .2017;54(4):2889-2900.

[25] Ham PB 3rd, Raju R. Mitochondrial function in hypoxic ischemic injury and influence of aging. Prog Neurobiol.2017; 157: 92-116.

[26] Keogh MJ, Chinnery PF. Mitochondrial DNA mutations in neurodegeneration. Biochim Biophys Acta.2015;1847(11): 1401-1411.

[27] Sun N, Youle RJ, Finkel T. The Mitochondrial Basis of Aging. Mol Cell.2016; 61(5): 654-666.

[28] Farkas E, Luiten PG, Bari F. Permanent, bilateral common carotid artery occlusion in the rat: a model for chronic cerebral hypoperfusion-related neurodegenerative diseases. Brain Res Rev. 2007;54(1): 162-180.

[29] Wang C, Zhao C, Li D, et al. Versatile Structures of alpha-Synuclein. Front Mol Neurosci 2016; 9: 48.

[30] Vargas KJ, Makani S, Davis T,et al. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci.2014; 34(28): 9364-9376.

[31] Devi L, Raghavendran V, Prabhu BM,et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem .2008; 283(14): 9089-9100.

[32] Nakamura K, Nemani VM, Wallender EK,et al. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria.J Neurosci.2008;28(47): 12305-12317.

[33] Robotta M, Gerding HR, Vogel A,et al. Alpha-synuclein binds to the inner membrane of mitochondria in an alpha-helical conformation. Chembiochem .2014; 15(17): 2499-2502.

[34] Pozo Devoto VM, Falzone TL. Mitochondrial dynamics in Parkinson's disease: a role for alpha-synuclein? Dis Model Mech .2017; 10(9): 1075-1087.

[35] Ludtmann MH, Angelova PR, Ninkina NN, et al. Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP Synthase. J Neurosci. 2016; 36(41): 10510-10521.

[36] Shen J, Du T, Wang X, et al. alpha-Synuclein amino terminus regulates mitochondrial membrane permeability. Brain Res. 2014;1591:14-26.

[37] Ellis CE, Murphy EJ, Mitchell DC,et al. Nussbaum, Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 2005; 25(22): 10190-10201.

[38] Chinta SJ, Mallajosyula JK, Rane A,et al.Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486(3): 235-239.

[39] Wong YC, Krainc D. alpha-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med.2017; 23(2): 1-13.

[40] Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain 2017; 140(2): 266-278.

[41] Lippa CF, Fujiwara H, Mann DM,et al.Trojanowski, Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol . 1998;153(5):1365-1370.

[42] Roberts HL, Schneider BL, Brown DR. alpha-Synuclein increases beta-amyloid secretion by promoting beta-/gamma-secretase processing of APP. PLoS One.2017; 12(2): e0171925.

[43] Guo JL, Covell DJ, Daniels JP,et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 2013;154(1):103-17.

[44] Peelaerts W, Baekelandt V. a-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem. 2016; 139 Suppl 1: 256-274.

[45] Larson ME, Greimel SJ, Amar F,et al.Selective lowering of synapsins induced by oligomeric alpha-synuclein exacerbates memory deficits. Proc Natl Acad Sci U S A.2017; 114(23): E4648-e4657.

[46] Martin ZS, Neugebauer V, Dineley KT, et al. Taglialatela, alpha-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem. 2012; 120(3): 440-452.

[47] Diógenes MJ, Dias RB, Rombo DM, et al.Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci. 2012;32(34): 11750-11762.

[48] Yasuda T, Nakata Y, Mochizuki H. alpha-Synuclein and neuronal cell death. Mol Neurobiol 2013; 47(2): 466-483.

[49] Lopez MS, Dempsey RJ, Vemuganti R. Resveratrol neuroprotection in stroke and traumatic CNS injury. Neurochem Int. 2015; 89: 75-82.

[50] Rodriguez-Grande B, Blackabey V, Gittens B,et al. Loss of substance P and inflammation precede delayed neurodegeneration in the substantia nigra after cerebral ischemia. Brain Behav Immun.2013; 29: 51-61.

[51] Polymeropoulos MH, Lavedan C, Leroy E,et al. Nussbaum, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science.1997; 276(5321): 2045-2047.

[52] Levine RL,Jones JC, Bee N. Stroke and Parkinson's disease. Stroke.1992; 23(6): 839-842.